Conduit Pharmaceuticals Inc. (CDT) is a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for oncology and rare diseases, addressing significant unmet medical needs. Leveraging its proprietary drug delivery technology, Conduit strives to enhance the efficacy and safety profiles of existing treatments, ultimately improving patient outcomes while minimizing adverse effects. Backed by an experienced management team and an emphasis on strategic partnerships, the company is strategically poised to advance its innovative product pipeline, aiming to make a transformative impact in the healthcare sector.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-24.74M |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -345.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-77.82 |
| Price-to-Book | 5.16 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -55.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.86M |
| Float | $2.26M |
| % Insiders | 35.09% |
| % Institutions | 0.00% |
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its Signature Intelligence platform into quantum-assisted coformer selection through SarborgQ, the Company's dedicated quantum computing division.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding its recent fundraise from a New York-based private investment fund.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that it has re-structured its debt, agreeing to pay off all outstanding amounts due under its Loan Notes with Alliance Global Partners (“A.G.P.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced that the Company received a written notice (“Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on May 21, 2026 indicating that the Company did not timely file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”), as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”).
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announces that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca, has progressed into the Patent Cooperation Treaty (“PCT”) phase, marking a significant step in the globalisation of its intellectual property (IP) protection.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual property and artificial intelligence-driven indication discovery.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the publication of its research paper titled “PRISM: cross-species connectivity mapping of plant intervention and stress signatures for translational agriculture.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that further expand the Company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis.
